证券代码：603102 证券简称：百合股份 公告编号：2022-031 威海百合生物技术股份有限公司 关于参加 2022 山东辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，威海百合生物技术股份有限公司（以下 简称"公司"）将参加由山东证监局指导、山东上市公司协会等单位联合举办的 2022 山东辖区上市公司投资者集体接待日活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录全景网"投资者关系互 动平台"（http://rs.p5w.net/），或关注微信公众号：全景财经，或下载全景路演 APP，参与本次互动交流，活动时间为 2022 年 11 月 16 日（周三）14:00-16:00。 届时公司高管将在线就公司业绩、公司治理、发展战略、经营状况等投资者关心 的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 威海百合生物技术股份有限公司董事会 2022 年 11 月 15 日 ...

威海百合生物技术股份有限公司 2022 年第三季度报告 2022 年第三季度报告 证券代码：603102 证券简称：百合股份 □是 √否 一、 主要财务数据 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 重要内容提示： 第三季度财务报表是否经审计 (一)主要会计数据和财务指标 1 / 18 单位：元 币种：人民币 项目 本报告期 本报告期比上 年同期增减变 动幅度(%) 年初至报告期 末 年初至报告期末 比上年同期增减 变动幅度(%) 营业收入 191,188,302.01 16.75 519,223,878.36 10.47 归属于上市公司股东的 净利润 34,981,203.41 -28.71 106,646,743.71 -9.59 归属于上市公司股东的 扣除非经常 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders for the same period was RMB 20 million, up 10% compared to the previous year[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a year-over-year growth of 15%[22]. - The company's revenue for the first half of the year reached ¥328,035,576.35, representing a 7.11% increase compared to the same period last year[23]. - Net profit attributable to shareholders was ¥71,665,540.30, up 4.03% year-over-year[23]. - The net profit after deducting non-recurring gains and losses increased by 10.88% to ¥68,329,583.25[23]. - The company has set a future outlook with a revenue target of 2.5 billion RMB for the full year 2022, which would require a 10% growth in the second half[22]. - The company achieved a revenue of 328.04 million RMB, representing a year-on-year growth of 7.11%[55]. - The total profit for the first half of 2022 was CNY 82,891,531.86, up from CNY 79,028,684.93 in the first half of 2021, reflecting a growth of 4.8%[126]. User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching a total of 500,000 users by June 30, 2022[1]. - User data indicates a growing customer base, with a 20% increase in active users compared to the previous year, reaching 500,000 users[22]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[1]. - The company is expanding its market presence, targeting a 25% increase in distribution channels across Asia by the end of 2022[22]. - The company plans to enhance its online sales platform, aiming for a 30% increase in e-commerce revenue by the end of 2022[22]. Research and Development - The company is investing RMB 5 million in R&D for new technologies aimed at enhancing product efficacy[1]. - The company is investing 50 million RMB in research and development for innovative nutritional products over the next two years[22]. - Research and development expenses decreased by 21.81% to 9.98 million RMB, reflecting a strategic focus on optimizing existing products[60]. - The company plans to enhance the development of infant supplementary foods, sports nutrition products, and special medical purpose formula foods[31]. - The company has a strong competitive advantage in R&D, with 25 invention patents and 64 health food approval certificates as of the reporting period[47]. Financial Position and Assets - The company has maintained a strong cash position with cash reserves of RMB 50 million as of June 30, 2022[1]. - The company's total assets grew by 68.79% to ¥1,545,939,184.26 compared to the end of the previous year[23]. - The company's cash and cash equivalents increased by 140.04% to 994.20 million RMB due to funds raised from its initial public offering[62]. - The company's total assets at the end of the first half of 2022 reached CNY 1,355,813,200.34, showing a robust asset base for future growth[140]. - The company's equity attributable to shareholders increased significantly to CNY 1,355,813,200.34 from CNY 713,716,609.84, reflecting a growth of approximately 90%[119]. Corporate Governance and Shareholder Information - The company announced the resignation of independent director Ji Yongsheng and the election of Li Bingsheng as a new independent director[66]. - Liu Luzeng resigned as a non-independent director, while Yao Jianwei was elected as a new non-independent director[66]. - The company confirmed that it is not a key pollutant discharge unit and has no relevant environmental information to disclose[70]. - The company’s actual controller and major shareholders have committed to not transferring their shares for 36 months post-IPO[73]. - Major shareholders, including Liu Xinqiang, are restricted from transferring shares for 36 months post-IPO, while other shareholders have a 12-month restriction[76][77]. Compliance and Legal Matters - The company guarantees that the prospectus for its initial public offering (IPO) does not contain false records, misleading statements, or significant omissions, and assumes joint legal responsibility for its authenticity, accuracy, completeness, and timeliness[85]. - The company will disclose any failure to fulfill commitments in a timely manner and will apologize to shareholders and the public[89]. - The company has not reported any significant changes in its financial condition or operations[102]. - There are no major related party transactions disclosed during the reporting period[103]. - The company has no significant litigation or arbitration matters during the reporting period[102]. Operational Efficiency - The production model combines "stock production" and "production based on sales," allowing for flexible resource allocation to meet customer demands[39]. - The sales model includes contract manufacturing and self-owned brands, with a focus on cash-on-delivery for most customers[40]. - The company has established a comprehensive procurement system to ensure the quality of over 200 raw materials used in production[35]. - Strict quality control measures are implemented for raw materials, including batch testing before production[38]. - The company has established a comprehensive raw material storage management system to ensure compliance with technical standards and requirements[37]. Future Outlook - Future guidance estimates a revenue growth of 20% for the full year 2022, projecting total revenue to reach RMB 220 million[1]. - New product launches are expected to contribute an additional RMB 15 million in revenue for the second half of 2022[1]. - The company plans to continue focusing on capital increases and strategic investments to support future growth initiatives[141]. - The company plans to enhance its product offerings in infant nutrition, sports nutrition, and special medical purpose foods[53]. - The company has initiated a strategic partnership with Mars Health for new product development, launching the "Light Body Nourishing Red Ginseng Iron Gummies"[56].

Financial Performance - The company's revenue for 2021 reached ¥661,874,435.29, representing a 14.45% increase compared to ¥578,287,203.18 in 2020[24]. - Net profit attributable to shareholders was ¥148,039,239.10, up 16.46% from ¥127,115,910.01 in the previous year[24]. - The net cash flow from operating activities was ¥169,149,696.97, reflecting a 12.77% increase from ¥149,997,634.85 in 2020[24]. - Total assets at the end of 2021 amounted to ¥915,918,074.40, a 25.84% increase from ¥727,851,850.89 in 2020[24]. - The company's net assets attributable to shareholders increased by 23.04% to ¥713,716,609.84 from ¥580,077,370.74 in 2020[24]. - Basic earnings per share for 2021 were ¥3.08, a 16.23% increase from ¥2.65 in 2020[25]. - The weighted average return on equity was 23.10%, down 1.15 percentage points from 24.25% in 2020[25]. - The company reported a net profit of ¥134,434,185.38 after deducting non-recurring gains and losses, which is a 14.62% increase from ¥117,291,383.17 in 2020[24]. - The diluted earnings per share also stood at ¥3.08, consistent with the basic earnings per share[25]. - The company achieved an operating revenue of 661.87 million RMB in 2021, representing a year-on-year growth of 14.45%[69]. - The net profit attributable to shareholders reached 148.04 million RMB, with a year-on-year increase of 16.46%[69]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 32 million RMB, which accounts for 21.62% of the net profit attributable to ordinary shareholders[4]. - The company has established a cash dividend policy, ensuring at least 10% of distributable profits are allocated for cash dividends[139]. - For the 2021 fiscal year, the proposed cash dividend is 5 RMB per 10 shares, pending approval from the shareholders' meeting[139]. - The cash dividend distribution plan aligns with the company's commitment to return at least 10% of distributable profits to shareholders annually, as per the A-share listing regulations[142]. Research and Development - The company's R&D investment in 2021 was 24.06 million yuan, accounting for 3.64% of operating income, representing a 15.98% increase from the previous year[34]. - The company holds 25 invention patents and 71 health food approval certificates, indicating strong R&D capabilities[59]. - The number of R&D personnel is 133, accounting for 13.50% of the total workforce, with 8 holding master's degrees and 41 holding bachelor's degrees[83]. - Research and development expenses amounted to 24,059,232.88 yuan, representing 3.64% of total operating revenue, with a year-on-year increase of 15.98%[82]. Market and Product Development - The company aims to enhance its product structure by developing infant supplementary foods, sports nutrition products, and specialized medical formula foods[40]. - The company plans to enhance the development of infant supplementary foods and sports nutrition products to strengthen its competitive advantage[65]. - The company plans to establish regional marketing centers in key cities across the country in 2022 to deepen customer demand and enhance service capabilities[35]. - The company aims to accelerate the development of its international market while expanding its domestic market presence in 2022[35]. - The company focuses on new product development and technological innovation to enhance competitiveness and adapt to market needs[36]. Corporate Governance - The board of directors guarantees the authenticity, accuracy, and completeness of the annual report[9]. - The company has implemented measures to ensure compliance with corporate governance standards, aligning with the Company Law and relevant regulations[119]. - The total pre-tax remuneration for the board members and senior management amounted to CNY 7.95 million in 2021, with no changes in shareholding during the reporting period[122]. - The company has a compensation and assessment committee responsible for formulating and reviewing the compensation policies for directors and senior management[126]. - The company has maintained effective internal controls over financial and non-financial reporting, with no significant deficiencies reported[148]. Risks and Challenges - The company has detailed potential risks in the report, urging investors to be cautious[10]. - The company faces risks related to product quality and food safety, which could impact its reputation and sales if not managed properly[109]. - Regulatory changes in food safety laws may significantly affect the long-term development and competitive landscape of the health food industry[110]. - The ongoing COVID-19 pandemic has posed challenges to the company's operations, affecting procurement, production, and sales channels[113]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 46, compared to 11,251 at the end of the previous month before the annual report disclosure[192]. - The top shareholder, Liu Xinli, holds 26,198,803 shares, representing 40.94% of the total shares[195]. - The second largest shareholder, Guangfa Xinde Investment Management Co., Ltd., holds 2,500,000 shares, accounting for 3.91%[195]. - Liu Xinli's shares are subject to a lock-up period until January 26, 2025, while Guangfa Xinde's shares are locked until January 26, 2023[197]. Operational Highlights - The company has established a comprehensive production capability for various dosage forms, including soft capsules, hard capsules, tablets, powders, oral liquids, and bottled drinks[40]. - The company has a production capacity exceeding 3.7 billion units per year, showcasing its scale production advantage[60]. - The company has a well-established marketing network covering over 30 provinces and regions in China, and its products are sold in more than 70 countries[68]. - The company operates in the nutrition and health food industry, benefiting from national policies promoting health and nutrition, which create a favorable environment for growth[39].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 146,138,526.49, representing a year-on-year increase of 1.12%[5] - The net profit attributable to shareholders decreased by 4.00% to CNY 31,101,485.21 compared to the same period last year[5] - The net profit for Q1 2022 was CNY 31,101,485.21, a decrease of 4.00% compared to CNY 32,396,564.27 in Q1 2021[18] - Operating profit for Q1 2022 was CNY 36,134,571.23, down from CNY 37,421,500.62 in the same period last year, reflecting a decline of 3.45%[18] - The total comprehensive income for Q1 2022 was CNY 31,101,485.21, down from CNY 32,396,564.27 in Q1 2021, a decline of 4.00%[18] - The company’s total profit for Q1 2022 was CNY 35,983,888.02, down from CNY 37,552,824.08 in Q1 2021, reflecting a decrease of 4.18%[18] Cash Flow and Liquidity - The net cash flow from operating activities significantly declined by 69.30% to CNY 13,518,587.35[5] - Cash flow from operating activities generated a net amount of CNY 13,518,587.35, significantly lower than CNY 44,036,838.22 in Q1 2021, indicating a decrease of 69.32%[21] - Total cash and cash equivalents at the end of Q1 2022 reached CNY 1,018,174,250.38, up from CNY 386,977,975.98 at the end of Q1 2021, representing an increase of 163.56%[22] - The company reported cash inflow from financing activities of CNY 616,056,184.48, compared to an outflow of CNY 14,400,000.00 in Q1 2021, marking a significant turnaround[22] - Cash outflow from investing activities was CNY 14,926,856.21, a decrease from CNY 27,378,543.65 in the previous year, indicating a reduction of 45.49%[22] - The company experienced a cash inflow of CNY 1,066,007.86 from other investment-related activities, compared to CNY 314,029.87 in Q1 2021, an increase of 239.77%[21] Assets and Liabilities - Total assets increased by 66.92% to CNY 1,528,826,501.74 compared to the end of the previous year[5] - Total assets as of March 31, 2022, amounted to CNY 1,528,826,501.74, an increase from CNY 915,918,074.40 at the end of 2021[15] - Total liabilities as of March 31, 2022, were CNY 181,577,356.49, a decrease from CNY 202,201,464.56 at the end of 2021[15] - Total equity attributable to shareholders as of March 31, 2022, was CNY 1,347,249,145.25, up from CNY 713,716,609.84 at the end of 2021[15] - Cash and cash equivalents as of March 31, 2022, were CNY 1,018,174,250.38, significantly higher than CNY 414,174,794.16 at the end of 2021[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,251[9] - The top ten shareholders held a combined 56.66% of the company's shares, with the largest shareholder owning 40.94%[9] Earnings and Expenses - The basic earnings per share for the period was CNY 0.53, unchanged from the previous year[5] - The basic and diluted earnings per share for Q1 2022 were both CNY 0.53, down from CNY 0.67 in Q1 2021, reflecting a decrease of 20.90%[18] - Total operating costs for Q1 2022 were CNY 108,512,966.16, a decrease of 0.4% from CNY 108,995,767.26 in Q1 2021[17] - Gross profit for Q1 2022 was CNY 37,625,560.33, resulting in a gross margin of approximately 25.7%[17] - Research and development expenses for Q1 2022 were CNY 4,774,889.11, down 19.1% from CNY 5,908,047.49 in Q1 2021[17] Government Subsidies - The company received government subsidies amounting to CNY 1,606,902.42, which are closely related to its normal business operations[6] Return on Equity - The weighted average return on equity increased by 5.52 percentage points to 2.75%[5]